Jessica Layne Berger, MD, gynecologic oncologist, University of Pittsburgh Medical Center Hillman Cancer Center, discusses chemotherapy delivery options for patients with ovarian cancer.

Historically, intraperitoneal (IP) chemotherapy was thought to increase the treatment effects because it could be delivered directly into the abdominal cavity where the tumors are located, explains Berger. Multiple clinical trials demonstrated improved survival with IP chemotherapy, despite increased toxicity.

For example, the phase III GOG-172 trial showed a survival benefit with intravenous (IV) paclitaxel plus IP cisplatin and paclitaxel versus IV paclitaxel and cisplatin in women with optimally debulked stage III ovarian cancer. However, only 42% of patients in the IP chemotherapy arm were able to complete 6 cycles of therapy.

Dose reductions and increased supportive care allowed more patients to complete the full course of treatment, but it remains a difficult regimen to give, says Berger.

Conversely, the phase III GOG-262 study showed that weekly dose-dense paclitaxel plus carboplatin did not prolong survival compared with carboplatin and paclitaxel, which was given every 3 weeks. However, 84% of patients opted to receive concurrent bevacizumab (Avastin), which may have contributed to the negative results, explains Berger.

As such, deciding between IV, IP, and dose-dense chemotherapy often comes down to personal preference, concludes Berger.

Videos

Jessica Layne Berger, MD, discusses chemotherapy delivery options for patients with ovarian cancer.

Dr. Berger on Chemotherapy Delivery Options in Ovarian Cancer

Jessica Layne Berger, MD, gynecologic oncologist, University of Pittsburgh Medical Center Hillman Cancer Center, discusses frontline treatment options in newly diagnosed advanced ovarian cancer.

Currently, platinum- and taxane-based chemotherapies are the standard of care in this patient population, explains Berger. However, chemotherapy can be given in a standard every-3-week fashion, a dose-dense fashion, or regionally with intraperitoneal (IP) chemotherapy. Moreover, chemotherapy can be given weekly without increasing the dose density to try to make it more tolerable for patients. These approaches allow for individualized treatment, says Berger.

IP chemotherapy is associated with a higher incidence of gastrointestinal toxicities, dehydration and electrolyte abnormalities versus dose-dense chemotherapy, says Berger. Additionally, abdominal port complications are common with IP chemotherapy.

Conversely, patients have a higher risk of developing anemia from dose-dense chemotherapy versus every-3-week dosing, says Berger. Additionally, the discontinuation rate may be higher with dose-dense chemotherapy compared with chemotherapy given every 3 weeks. 

Jessica Layne Berger, MD, discusses the frontline treatment options in newly diagnosed ovarian cancer.

Jessica Layne Berger, MD

Articles

Dr. Berger on Chemotherapy Delivery Options in Ovarian Cancer

Dr. Berger on Frontline Treatment Options in Newly Diagnosed Advanced Ovarian Cancer